Cargando…

Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2(−/−) mice by modulating composition, signalling and excretion of faecal bile acids

BACKGROUND AND AIMS: Interruption of the enterohepatic circulation of bile acids (BAs) may protect against BA-mediated cholestatic liver and bile duct injury. BA sequestrants are established to treat cholestatic pruritus, but their impact on the underlying cholestasis is still unclear. We aimed to e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fuchs, Claudia Daniela, Paumgartner, Gustav, Mlitz, Veronika, Kunczer, Victoria, Halilbasic, Emina, Leditznig, Nadja, Wahlström, Annika, Ståhlman, Marcus, Thüringer, Andrea, Kashofer, Karl, Stojakovic, Tatjana, Marschall, Hanns-Ulrich, Trauner, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109278/ https://www.ncbi.nlm.nih.gov/pubmed/29636383 http://dx.doi.org/10.1136/gutjnl-2017-314553

Ejemplares similares

Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2(−/−) mouse model of sclerosing cholangitis via immunomodulatory effects
por: Fuchs, Claudia D., et al.
Publicado: (2022)

The role of bile acids in cholestatic liver injury
por: Cai, Shi-Ying, et al.
Publicado: (2021)

Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption
por: Kårhus, Martin Lund, et al.
Publicado: (2021)

Bile acid transporters and regulatory nuclear receptors in the liver and beyond
por: Halilbasic, Emina, et al.
Publicado: (2013)

Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH
por: Al-Dury, Samer, et al.
Publicado: (2018)

Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases
por: Halilbasic, Emina, et al.
Publicado: (2013)

Cyp3a11 is not essential for the formation of murine bile acids
por: Wahlström, Annika, et al.
Publicado: (2017)

Ursodeoxycholic acid enriches intestinal bile salt hydrolase-expressing Bacteroidetes in cholestatic pregnancy
por: Ovadia, Caroline, et al.
Publicado: (2020)

The analysis of gut microbiota in patients with bile acid diarrhoea treated with colesevelam
por: Kumar, Aditi, et al.
Publicado: (2023)

Absence of Bsep/Abcb11 attenuates MCD diet‐induced hepatic steatosis but aggravates inflammation in mice
por: Fuchs, Claudia D., et al.
Publicado: (2020)

Diagnostic role of the ‘white test’ with lipidic solution in the early intraoperative identification of open bile ducts for the prevention of bile leakage after liver resection: study protocol for a randomised controlled multicentric superiority trial (BiLe-Trial)
por: Cristaudi, Alessandra, et al.
Publicado: (2021)

Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis
por: Gui, Wenfang, et al.
Publicado: (2023)

Bile Acid Sequestration via Colesevelam Reduces Bile Acid Hydrophobicity and Improves Liver Pathology in Cyp2c70(−/−) Mice with a Human-like Bile Acid Composition
por: Palmiotti, Anna, et al.
Publicado: (2023)

Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis
por: Al-Dury, Samer, et al.
Publicado: (2018)

Bile Duct Repair in Human Liver Grafts: Effective Cholangiocyte Organoid Engraftment and Plasticity
por: van der Laan, Luc J.W., et al.
Publicado: (2021)

Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity
por: Mueller, Michaela, et al.
Publicado: (2015)

Bile Nephropathy in Flucloxacillin-Induced Cholestatic Liver Dysfunction
por: Alnasrallah, Basil, et al.
Publicado: (2016)

Variation in Bile Microbiome by the Etiology of Cholestatic Liver Disease
por: Tyc, Olaf, et al.
Publicado: (2020)

Bile acid-mediated signaling in cholestatic liver diseases
por: Zeng, Jing, et al.
Publicado: (2023)

Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease
por: Traussnigg, Stefan, et al.
Publicado: (2020)

Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2(-/-) mouse model of sclerosing cholangitis
por: Fuchs, Claudia D., et al.
Publicado: (2023)

Home-based exercise in patients with refractory fatigue associated with primary biliary cholangitis: a protocol for the EXerCise Intervention in cholesTatic LivEr Disease (EXCITED) feasibility trial
por: Freer, Alice, et al.
Publicado: (2021)

Bile acids decrease intracellular bilirubin levels in the cholestatic liver: implications for bile acid-mediated oxidative stress
por: Muchova, Lucie, et al.
Publicado: (2011)

Hepatocyte specific expression of an oncogenic variant of β-catenin results in cholestatic liver disease
por: Lemberger, Ursula J., et al.
Publicado: (2016)

Pathobiochemical signatures of cholestatic liver disease in bile duct ligated mice
por: Abshagen, Kerstin, et al.
Publicado: (2015)

MRGPRX4 is a bile acid receptor for human cholestatic itch
por: Yu, Huasheng, et al.
Publicado: (2019)

Crosstalk between Gut Microbiota and Bile Acids in Cholestatic Liver Disease
por: Shi, Qingmiao, et al.
Publicado: (2023)

Hormesis in Cholestatic Liver Disease; Preconditioning with Low Bile Acid Concentrations Protects against Bile Acid-Induced Toxicity
por: Verhaag, Esther M., et al.
Publicado: (2016)

Faecal bile acids and clostridia in patients with breast cancer.
por: Murray, W. R., et al.
Publicado: (1980)

Faecal bile acids and clostridia in the aetiology of colorectal cancer.
por: Murray, W. R., et al.
Publicado: (1980)

Effect of Plasmapheresis on Cholestatic Pruritus and Autotaxin Activity During Pregnancy
por: Heerkens, Marieke, et al.
Publicado: (2019)

GLP-2 Improves Hepatic Inflammation and Fibrosis in Mdr2(-/-) Mice Via Activation of NR4a1/Nur77 in Hepatic Stellate Cells and Intestinal FXR Signaling
por: Fuchs, Claudia D., et al.
Publicado: (2023)

Oral Cholic Acid Is Efficacious and Well Tolerated in Patients With Bile Acid Synthesis and Zellweger Spectrum Disorders
por: Heubi, James E., et al.
Publicado: (2017)

The protective effect of allopurinol on cholestatic liver injury induced by bile duct ligation.
por: Mun, K. C., et al.
Publicado: (1996)

Highlight report: Protection of cholestatic livers by shunting of bile from canaliculi to sinusoids
por: Abbass, Tahany, et al.
Publicado: (2018)

Studies on the mechanisms of bile acid initiated hepatic inflammation in cholestatic liver injury
por: Cai, Shi-Ying, et al.
Publicado: (2017)

Investigating bile acid-mediated cholestatic drug-induced liver injury using a mechanistic model of multidrug resistance protein 3 (MDR3) inhibition
por: Beaudoin, James J., et al.
Publicado: (2023)

Predictive value of faecal calprotectin in ulcerative colitis – single centre experience
por: Grgić, Dora, et al.
Publicado: (2022)

Associations between Dietary Patterns and Bile Acids—Results from a Cross-Sectional Study in Vegans and Omnivores
por: Trefflich, Iris, et al.
Publicado: (2019)

Protocol for faecal microbiota transplantation in ulcerative colitis (FMTUC): a randomised feasibility study
por: Jitsumura, Maki, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cq88johc480kq3m6kujhuq8lul